anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Avirulent strains of Brucella abortus are cultivated in a nutrient medium containing an adequate carbon source which is fructose, or contains at least 0.1% w/v. fructose in respect of the medium, or at least 2.5% w/w. fructose in proportion to the total carbon source, the culture then being freeze dried to give a living vaccine of the micro-organism. The preferred strain of organism is S.19; the medium is of conventional constitution regarding components other than fructose, the latter suitably being present in about 4% w/v. concentration.  Alternatively, the carbon source may be, e.g. about 4% w/v. of a 3:1 by weight mixture of glucose with fructose. Preferably sucrose, about 5% w/v. is added to the culture before freeze drying, as as a stabilizer.  Cultivation in the presence of fructose is said to increase the number of viable organisms in the freeze-dried product, and to improve its stability on storage.ALSO:Living Brucella abortus vaccines are prepared by cultivating a non-virulent strain thereof in a nutrient medium, having an adequate carbon source which is fructose or contains at least 0.1% w/v. fructose in respect of the medium, or at least 2.5% w/w. fructose in proportion to the total carbon source, and freeze-drying the resulting culture.  The preferred strain is the S.19 strain.  A suitable additional carbon source is glucose. Before freeze-drying, sucrose is preferably added to the culture, to about 5% w/v. concentration, to improve the stability of the vaccine.  The presence of fructose as a carbon source is said to increase the number of viable organisms in the vaccine after freeze-drying, and to improve its storage stability.
Antihypertensive drugs may cause various side effects, including degradation of liver and kidney functions, which adversely affect blood circulation, resulting in hyperlipidemia, arteriosclerosis and cardiovascular and cerebrovascular diseases. In addition, antihypertensive drugs cause lack of oxygen in the brain and osteoporosis, and reduce white blood cells, red blood cells and thrombocytes and degrade immune functions to cause an increase in vulnerability to infectious diseases. Therefore, there is a need for a highly effective antihypertensive drug having high safety during long-term administration. The present inventors have conducted intensive studies for 4.6 years based on knowledge about medical science, combinations of medicinal herbs, foods for therapy, and the like, and developed a safe and highly effective antihypertensive drug. The present invention provides a composition for alleviating hypertension, including a combination of: (1) 58% of garlic, 20% of fig fruit powder, 10% of ginger, 10% of eggplant powder and 2% of lotus root; and (2) 55% of apples, 8% of walnuts, 10% of black beans, 10% of mung beans, 10% of white radish, 5% of citron powder and 2% of lotus root. The composition has high commercial applicability, considering a significantly large world market of antihypertensive drugs.
Oral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase.
PURPOSE: A composition containing diosgenin or pharmaceutically acceptable salt thereof is provided to promote proliferation, differentiation, and mineralization of osteoblast. CONSTITUTION: A composition for promoting osteoblast contains diosgenin or pharmaceutically acceptable salt thereof. Diosgenin is isolated from yam. The concentration of the diosgenin is 1-3 uM. A composition for preventing or treating bone metabolism contains diosgenin or pharmaceutically acceptable salt thereof. The bone metabolism is osteoporosis, bone metastatic lesion, rheumatic or degenerative arthritis, periodontal diseases, inflammatory bone absorption or Paget's disease. A food composition for improving bone function contains diogenin or pharmaceutically acceptable salt.
A regenerative device can include a first side section, a second side section, and a top section extending between and connecting the first side section and the second side section. The top section and the first and second side sections can each be formed from a porous material that retains its structure after implantation in the patient. The regenerative device can be used for ridge augmentation of a maxilla or a mandible. The top section can include an opening configured for receiving an implant. The porous material can be permanently implanted in the mouth and promote bone regeneration or ridge augmentation. The first and second side sections of the device can include openings for receiving a fastener to secure the device to the alveolar ridge.
Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). rhTPO began on the last day of ICE (Ifosfamide, Carboplatin and Etoposide) chemotherapy (Day 4) and subsequent doses will be administered on Days 6, 8, 10 and 12 (5 doses total). The initial dose of rhTPO was 1.2 μg/kg/dose and was subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one only).
PURPOSE:To obtain an antihypertensive agent free from side effects, containing an extract which has association relationship to organisms, high safety and is prepared by extracting a cell of bacterium belonging to the genus Streptococcus or Enterococcus with water. CONSTITUTION:A cell of bacterium belonging to the genus Streptococcus or Enterococcus is extracted with warm water at >=50 deg.C and the cell is removed after the extraction to give an extracted solution. The extracted solution is concentrated and dried as it is and used as an antihypertensive agent. Further preferably salts and other low-molecular substances are removed from the extracted solution by dialysis, etc., to give a more effective antihypertensive agent. The extract of cell or the antihypertensive agent has no toxicity at all or extremely low toxicity. The antihypertensive agent can be administered orally and by injection. The antihypertensive agent has intermediate effects, durable effects and is inexpensive. The antihypertensive agent is not only used as a drug but also is added to foods and usable for preventing and treating hypertension.
INTRODUCTION: B cell exhaustion is a functional abnormality of B lymphocytes observed in chronic infections and shows association with autoreactivity. The role of exhausted and classical memory B cells in maintaining disease stability of lupus nephritis (LN) remains unclear.
METHODS: We measured classical memory (CD19+CD21+CD27+), exhausted B cells (CD19+CD21-CD27-), and related cytokines in LN patients with multiple relapses (MR) (n = 15) and no relapse (NR) (n = 15) during disease remission. The expression of inhibitory/adhesion molecules, cell proliferation and calcium mobilization in classical memory and exhausted B cells were also assessed.
RESULTS: The MR group had higher proportion of circulating exhausted and classical memory B cells compared to the NR group and healthy controls (HC) (p all <0.05 for MR vs. NR or HC). Blood levels of IL-6, BAFF, IL-21, CD62L, CXCR3 and Siglec-6 were all higher in the MR group (p < 0.05, for all). Exhausted B cells from the MR group showed higher FcRL4, CD22, CD85j and CD183 but lower CD62L expression than NR and HC groups. Exhausted B cells from MR patients exhibited reduced proliferation compared to NR patients and HC, while classical memory B cell proliferation in MR group was higher than the other two groups. Exhausted B cells from both MR and NR patients showed impaired calcium mobilization.
CONCLUSION: Alterations in exhausted and classical memory B cells are related to disease relapse in LN. These findings may help devise new strategies for monitoring disease activity and preventing relapse in LN.
PURPOSE: Metabolic and bariatric surgery (MBS) has been shown to enhance the quality of life (QoL) in individuals with obesity. The Bariatric Analysis and Reporting Outcome System (BAROS) is a highly reliable scoring system utilized to assess weight loss, obesity-associated medical conditions, and QoL following MBS. This study aimed to assess the efficacy of sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and one anastomosis gastric bypass (OAGB) in improving health outcomes for individuals with severe obesity, employing the BAROS questionnaire.
METHODS: A retrospective study was conducted, enrolling 299 patients with a body mass index (BMI) of 40 or higher who had undergone primary MBS (RYGB, OAGB, or SG) and had a 5-year follow-up. Patients were evaluated using the BAROS scoring system, which included measures of % excess weight loss (%EWL), improvement and remission of obesity-related medical problems, and postoperative short-term and long-term complications.
RESULTS: The mean age and pre-op BMI of the patients was 39.4 ± 9.4 years and 44.6± 6.5 kg/m2, respectively. The total BAROS score was significantly higher in patients who underwent OAGB compared to those who underwent RYGB and SG (P, 0.02). However, no significant differences were observed in other aspects of the BAROS score, such as QoL.
CONCLUSION: This study demonstrated that all three common metabolic and bariatric surgical procedures (SG, RYGB, and OAGB) significantly improved the QoL after surgery. Furthermore, patients who underwent OAGB had a significantly higher total BAROS score at the 5-year follow-up compared to those who underwent RYGB and SG.
BACKGROUND: Thyroid dysfunction exhibits a heightened prevalence among people with diabetes compared to those without diabetes. Furthermore, TD emerges as a notable correlated risk factor for the onset of diabetic retinopathy.
METHODS: Using data from the FinnGen database (R9), we investigated the causal relationship between thyroid dysfunction (TD) and four stages of diabetic retinopathy (DR). A two-sample univariable Mendelian randomization (UVMR) approach was employed to estimate the total causal effect of TD on four stages of DR, while multivariable Mendelian randomization (MVMR) was used to assess the direct causal effect. The meta-analysis was conducted to summarize the collective effect of TD on four stages of DR. The inverse variance weighted (IVW) method was the primary approach for Mendelian randomization analysis, with heterogeneity, horizontal pleiotropy, and leave-one-out sensitivity analyses performed to validate the robustness of the findings.
RESULTS: In UVMR analysis, thyrotoxicosis (TOS) was significantly associated with an increased risk of diabetic retinopathy across four stages (OR, 1.10-1.19; P<0.025). However, MVMR analysis, after adjusting for Graves' disease (GD) and/or rheumatoid arthritis (RA), revealed no significant association between TOS and the four stages of diabetic retinopathy. The Meta-analysis demonstrated the collective effect of TOS on diabetic retinopathy across all stages [OR=1.11; 95% CI (1.08-1.15); P<0.01]. In UVMR analysis, the estimates for hypothyroidism (HPT) and GD were similar to those for TOS. In the MVMR analysis, after adjusting for RA, the significant effect of HPT on DR and non-proliferative diabetic retinopathy (NPDR) remained. Additionally, MVMR analysis suggested that the estimates for GD on DR were not affected by TOS, except for GD-proliferative diabetic retinopathy (PDR). However, no significant correlation persisted after adjusting for RA, including for GD-PDR.
CONCLUSION: Our study demonstrated a significant association between thyroid dysfunction TD and DR, with the relationship being particularly pronounced in HPT-DR.
Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin two weeks after surgery.
The main purpose of this study is to investigate the safety and tolerability of intermittent Theta Burst (iTBS), its effectiveness in alleviating depressive symptoms, concomitant neuropsychiatric symptoms such as anxiety and fatigue in people with MS, as well as its effects on cognition. Although iTBS repetitive transcranial magnetic stimulation (rTMS) is approved for use in major depressive disorder (MDD), there have been no safety and tolerability evaluations of this form of rTMS in Multiple Sclerosis (MS) patient with MDD. Although iTBS rTMS has previously been found safe and effective for treating spasticity in people with MS, this will be the first study to investigate the safety and tolerability of Left Dorsolateral Prefrontal Cortex (L-DLPFC) iTBS rTMS for MDD in MS

This study is designed as an open-label pilot study. Participants will undergo baseline evaluations to confirm a diagnosis of MDD and to assess your eligibility for rTMS treatment. If deemed eligible, participants will receive iTBS treatment. iTBS is a form of rTMS approved by Health Canada for treatment of MDD. iTBS rTMS treatment involves 3 minutes of non-invasive brain stimulation, 5 days a week, for 4 weeks, for a total of 20 treatments. While receiving iTBS rTMS, participants will be seen daily by the rTMS operator who is a mental health nurse. While receiving iTBS rTMS, participants will see the research coordinator and study psychiatrist on a weekly basis, to complete clinical assessments to evaluate their neuropsychiatric symptoms and assess any side effects from the rTMS procedure. As part of the suggested pathophysiological profile of depression the levels of inflammatory cytokines tumor necrosis factor ⍺ (TNF-⍺) and interleukin-6 (IL-6) have shown elevated concentration levels in plasma of depressed compared to non-depressed individuals. In this study, we aim to investigate the levels of these inflammatory cytokine markers and their change with iTBS.
Mirvetuximab soravtansine-gynx (MIRV) is a conjugate of a folate receptor alpha (FRα)-directed antibody and the maytansinoid microtubule inhibitor, DM4. Accumulating pre-clinical and clinical data supported the safety and anti-tumor activity of MIRV in tumors expressing FRα. In 2017, a phase I expansion study reported the first experience of MIRV in FRα-positive platinum-resistant ovarian cancer with promising results. However, the phase III FORWARD I study failed to demonstrate a significant benefit of MIRV in FRα-positive tumors. On the basis of the data reported from this latter study, MIRV was then explored in the FRα-high population only and using a different folate receptor assay. The phase II SORAYA trial supported the adoption of MIRV in this setting. Hence, the US Food and Drug Administration granted accelerated approval of MIRV for patients with FRα-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. Moreover, the results of the MIRASOL trial showed a significant reduction in the risk of tumor progression or death among patients treated with MIRV versus chemotherapy. VENTANA FOLR1 (FOLR-2.1) was approved as a companion diagnostic test to identify FRα patients. MIRV appears to be a significant asset in managing advanced or recurrent ovarian cancer. Further trials are needed to confirm these promising results, even in the neoadjuvant, adjuvant, and maintenance settings.
Threonine is resolved into its optically active forms by dissolving enough DL-threonine in water or aqueous alcohol at an elevated temperature to produce a solution which is supersaturated at room temperature, adding to the hot solution a small amount of one of the active forms and cooling to effect crystallization of the active form.  The mother liquor may be heated and further DL-threonine added, whereby the other active form crystallizes on cooling.  This process may be repeated indefinitely.  In a modification the DL-threonine is used in part as a soluble acid-addition salt such as the hydrochloride, the mixture of base and salt being obtained either by partial acidification of free threonine or partial addition of an inorganic or organic base to a threonine salt.  The amount of active form added to start the process may be 2-12 per cent by weight of racemic form.  The solution is preferably cooled through a range of 20-60 DEG  C., the crystallization temperature being 20 DEG  C. or below.  The crystallized threonine can be freed from any DL-form present by recrystallization.  The D(+)-form may, if desired, be converted into the more valuable L(-)-form.
In Stage 2, participants received the RP2D on the basis of the MTD or maximum allowed dose (MAD) of the combination treatment established in Stage 1. Treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC will be included.
Stable homogeneous aqs. suspensions contain guar gum and a therapeutically active substance (not a barium salt) insoluble in water. These are useful for treating intestinal disorders; the guar gum enables stable suspensions to be made from substances previously difficult to suspend in water. The active substance may be a Ca, Al, Mg or Bi salt (pref. aluminium tetrbasic phytate, bismuth subnitrate, or tricalcium phosphate) or an organic substance (pref. terpinol or benzonaphthol). An adjuvant, such as pectin, sorbitol, glycerine, or propylene glycol, which improves the properties of gels, may also be present. In examples, 0.3% aqs. soln. of guar gum is used, and the gum forms 0.20-0.45% of the weight of the active ingredient.
A total of 105 patients with atrial fibrillation (AF) are scheduled to receive surgical treatment and will be divided into three groups. Left atrial appendage occlusion (LAAC), three-dimensional mapping guided radiofrequency ablation and LAAC combined radiofrequency ablation (1:1:1) were performed respectively. All patients were examined by real-time three-dimensional and two-dimensional ultrasound before operation, 1 and 3 months after operation to measure left atrial (LA) function. All ultrasound data will be stored and the professional director of the ultrasound room will be invited for quantitative analysis. The ultrasound indexes include: left atrial diameter, left atrial ejection fraction, etc. All patients underwent transesophageal echocardiography before operation and 3 months after the operation. Results two experienced ultrasound doctors judged whether there was left atrial thrombus, residual shunt and instrument surface related thrombus. The routine blood test and high-sensitivity C-reactive protein were performed in all patients before operation, 1 day and 1 month after operation. B-type natriuretic peptide was detected in all patients before operation and 1 day, 1 month and 3 months after operation. All patients underwent 6-minute walking test and quality of life score before operation, 1 and 3 months after operation. At the same time, the thickness of crista was measured in all patients. This study will clarify the changes of left atrial function and biochemical quality in patients with AF after LAAC. In addition, this study also observed the effect of radiofrequency ablation combined with LAAC on left atrial function and evaluated whether one-stop surgery has more advantages than simple occlusion or ablation, and analyzed the above results. The patients were followed up for an average of three months to analyze the changes of left atrial function, quality of life and embolism events.
Introduction: Stress related disorders may lead to mental disorders as well as cardiovascular problems. They may also result in absenteeism and less productivity in companies. This protocol proposes a well-being program based on meditation and Positive Psychology principles such as human development, the improvement of virtues, quality of life and well-being. The investigators hypothesize that this program may promote well-being and reduce stress related problems in the participants. Objectives: To evaluate the efficacy of a well-being and quality of life program in a sample of managers who work in a company (Natura Inovação/Cosméticos ) and health care professionals who work in a hospital (Hospital Israelita Albert Einstein) as well as its implication in the work environment. Methods:Sixty participants from Natura Inovação/Cosméticos and 60 health professionals from Hospital Israelita Albert Einstein will be recruited. The participants will be randomized in two groups of 30 participants each one, half of them in the control group (GC) and the other half to the intervention group (GI). This is a cross-over study. After the first evaluation GI will participate in the Flourishing Program for 8 weeks and the GC will be a wait-list group in this period of time. After that, there is a second evaluation of the participants and the GC will receive the intervention (Flourishing Program). GI will not receive any intervention during this new period of 8 weeks. A final evaluation will happen after that. The participants will fill in questionnaires (to evaluate depression, anxiety, stress, positive and negative affects, sleep quality, self-compassion, mindfulness, virtues, values, happiness, psychological well-being) and will be clinically examined; their blood sample will be collected (for the dosage of health related biomarkers) and also saliva for cortisol measures. They will perform structural and functional neuroimaging exams (emotional and cognitive paradigms) and their physiological measures such as skin conductance will be recorded.
All Subjects will receive AGS-8M4 treatment. Subjects will be enrolled into 1 of 2 treatment arms according to their disease status. A disease assessment will be performed every 8 or 9 weeks (± 3 days) depending on the treatment arm assignment. The assessment will be based both on changes in clinical symptoms, and radiographic images. Subjects without evidence of disease progression may continue to receive treatment based on their original treatment assignment until disease progression or intolerability. A safety follow-up visit will occur 4 weeks after the last dose infusion of AGS-8M4.
Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
Gallbladder cancer (GBC) is a rare disease with a poor prognosis. Simple cholecystectomy may be an adequate treatment only for very early disease (Tis, T1a), whereas reoperation is recommended for more advanced disease (T1b and T2). Radical cholecystectomy should have two fundamental objectives: To radically resect the liver parenchyma and to achieve adequate clearance of the lymph nodes. However, recent studies have shown that compared with lymph node dissection alone, liver resection does not improve survival outcomes. The oncological roles of lymphadenectomy and liver resection is distinct. Therefore, for patients with incidental GBC without liver invasion, hepatic resection is not always mandatory.
Method and apparatus for performing multiple measurements and diagnoses include a data acquisition module, a data processing module, an optional treatment output module, a user control module, and a user display system, where the data acquisition module sends a plurality of measurement data simultaneously to the data processing module. The data processing module provides a plurality of outputs which can be made available to the user or combined in the diagnostic module. A treatment algorithm in the treatment module can affect the patient through a feedback mechanism. In response, the data processing module generates treatment information needed by the treatment output module. In one embodiment, the data acquisition module sends multiple different measurement data relating to one or more diseases to the data processing module. In response to further measurements of the parameters, an effectiveness of the treatment can be determined and the treatment regimen can be modified, as necessary.